Thymosin α1: A historical overview

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 14-20

  Garaci, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Combination therapies; Thymosin 1

Indexed keywords

ALPHA INTERFERON; AMANTADINE; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RIBAVIRIN; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR; DRUG DERIVATIVE; HLA ANTIGEN CLASS 1; THYMOSIN;

CANCER INHIBITION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CYTOKINE PRODUCTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREGULATION; INFLUENZA VIRUS A; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PROTEIN EXPRESSION; VIRUS INFECTION; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; HISTORY; MOLECULAR GENETICS; PHYSIOLOGY; THYMOMA;

HEPATITIS C VIRUS;

AMINO ACID SEQUENCE; ANIMALS; CYCLOPHOSPHAMIDE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTORY, 20TH CENTURY; HUMANS; MOLECULAR SEQUENCE DATA; THYMOSIN; THYMUS NEOPLASMS;

EID: 35348982764     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.039     Document Type: Conference Paper

References (21)

1. MILLER, J.F. 1961. Immunological function of the thymus. Lancet 2: 748-749.
2. GOOD, R.A., A.P. DAL MASSO, C. MARTINEZ, et al. 1962. The role of the thymus in development of immunologic capacity in rabbits and mice. J. Exp. Med. 116: 773-796.
3. KLEIN, J.J., A.L. GOLDSTEIN & A. WHITE. 1965. Enhancement of in vivo incorporation of labeled precursors into DNA and total protein of mouse lymph nodes after administration of thymic extracts. Proc. Natl. Acad. Sci. USA 53: 812-817.
4. GOLDSTEIN, A.L., F.D. SLATER & A. WHITE. 1966. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc. Natl. Acad. Sci. USA 56: 1010-1017.
5. GOLDSTEIN, A.L., T.L. LOW, M. MCADOO, et al. 1977. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. USA 74: 725-729.
6. CHRETIEN, P.B., S.D. LIPSON, R. MAKUCH, et al. 1978. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treat. Rep. 62: 1787-1790.
7. SCHULOF, R.S., M.J. LLOYD, J.J. STALLINGS, et al. 1985. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. J. Biol. Response Mod. 4: 310-323.
8. FAVALLI, C., T. JEZZI, A. MASTINO, et al. 1985. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol. Immunother. 20: 189-192.
9. LEICHTLING, K.D., S.A. SERRATE & M.B. SZTEIN. 1990. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmacol. 12: 19-29.
10. GARACI, E., A. MASTINO, F. PICA, et al. 1990. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. 32: 154-160.
11. MASTINO, A., C. FAVALLI, S. GRELLI, et al. 1992. Combination therapy with thymosin-a1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer 50: 493-499.
12. GARACI, E., F. PICA, A. MASTINO, et al. 1993. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother. Emphasis Tumor Immunol. 13: 7-17.
13. FAVALLI, C., A. MASTINO, T. JEZZI, et al. 1989. Synergic effect of thymosin alpha 1 and alpha-beta interferon on nk activity in tumor-bearing mice. Int. J. Immunopharmacol. 11: 443-450.
14. RASI, G., G. SILECCHIA, P. SINIBALDI- VALLEBONA, et al. 1994. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int. J. Cancer 57: 701-705.
15. GIULIANI, C., G. NAPOLITANO, A. MASTINO, et al. 2000. Thymosin-alpha1 regulates MHCclass I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30: 778-786.
16. D'AGOSTINI, C., A.T. PALAMARA, C. FAVALLI, et al. 1996. Efficacy of combination therapy with amantadine, thymosin a1 and a/b interferon in mice infected with influenza A virus. Int. J. Immunopharmacol. 18: 95-102.
17. BISTONI, F., P. MARCONI, L. FRATI, et al. 1982. Increase of mouse resistance to Candida albicans infection by thymosin alpha 1. Infect. Immun. 36: 609-614.
18. ROMANI, L., F. BISTONI, R. GAZIANO, et al. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
19. ROMANI, L., F. BISTONI, K. PERRUCCIO, et al. 2006. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.
20. LOPEZ, M., S. CARPANO, R. CAVALIERE, et al. 1994. Biochemotherapy with thymosin-a1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann. Oncol. 5: 741-746.
21. GARACI, E., M. LOPEZ, G. BONSIGNORE, et al. 1995. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur. J. Cancer 13/14: 2403-2405.